Erin M Siegel1, Steven Eschrich, Kathryn Winter, Bridget Riggs, Anders Berglund, Abidemi Ajidahun, Jeff Simko, Jennifer Moughan, Jaffer Ajani, Anthony Magliocco, Abul Elahi, Sarah Hoffe, David Shibata. 1. 1Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida 2Department of Biomedical Informatics, Moffitt Cancer Center, Tampa, Florida 3Department of Statistics, Radiation Therapy Oncology Group, Philadelphia, Pennsylvania 4Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida 5Biospecimen Resource, Radiation Therapy Oncology Group, San Francisco, California 6Department of Medical Oncology, M.D. Anderson Cancer Center, Houston, TX 7Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, Florida 8Department Radiation Oncology, Moffitt Cancer Center, Tampa, Florida.
Abstract
BACKGROUND: The Radiation Therapy Oncology Group 98-11 clinical trial demonstrated the superiority of standard 5-fluorouracil/mitomycin-C over 5-fluorouracil/cisplatin in combination with radiation in the treatment of anal squamous cell cancer. Tumor size (>5 cm) and lymph node metastases are associated with disease progression. There may be key molecular differences (eg, DNA methylation changes) in tumors at high risk for progression. OBJECTIVE: The objectives of this study were to determine whether there are differences in DNA methylation at individual CpG sites and within genes among locally advanced anal cancers, with large tumor size and/or nodal involvement, compared with those that are less advanced. DESIGN: This was a case-case study among 121 patients defined as high risk (tumor size >5 cm and/or nodal involvement; n = 59) or low risk (≤5 cm, node negative; n = 62) within the mitomycin-C arm of the Radiation Therapy Oncology Group 98-11 trial. DNA methylation was measured using the Illumina HumanMethylation450 Array. SETTINGS: The study was conducted in a tertiary care cancer center in collaboration with a national clinical trials cooperative group. PATIENTS: The patients consisted of 74 women and 47 men with a median age of 54 years (range, 25-79 years). MAIN OUTCOME MEASURES: DNA methylation differences at individual CpG sites and within genes between low- and high-risk patients were compared using the Mann-Whitney test (p < 0.001). RESULTS: A total of 16 CpG loci were differentially methylated (14 increased and 2 decreased) in high- versus low-risk cases. Genes harboring differentially methylated CpG sites included known tumor suppressor genes and novel targets. LIMITATIONS: This study only included patients in the mitomycin-C arm with tumor tissue; however, this sample was representative of the trial. CONCLUSIONS: This is the first study to apply genome-wide methylation analysis to anal cancer. Biologically relevant differences in methylated targets were found to discriminate locally advanced from early anal cancer. Epigenetic events likely play a significant role in the progression of anal cancer and may serve as potential biomarkers.
RCT Entities:
BACKGROUND: The Radiation Therapy Oncology Group 98-11 clinical trial demonstrated the superiority of standard 5-fluorouracil/mitomycin-C over 5-fluorouracil/cisplatin in combination with radiation in the treatment of anal squamous cell cancer. Tumor size (>5 cm) and lymph node metastases are associated with disease progression. There may be key molecular differences (eg, DNA methylation changes) in tumors at high risk for progression. OBJECTIVE: The objectives of this study were to determine whether there are differences in DNA methylation at individual CpG sites and within genes among locally advanced anal cancers, with large tumor size and/or nodal involvement, compared with those that are less advanced. DESIGN: This was a case-case study among 121 patients defined as high risk (tumor size >5 cm and/or nodal involvement; n = 59) or low risk (≤5 cm, node negative; n = 62) within the mitomycin-C arm of the Radiation Therapy Oncology Group 98-11 trial. DNA methylation was measured using the Illumina HumanMethylation450 Array. SETTINGS: The study was conducted in a tertiary care cancer center in collaboration with a national clinical trials cooperative group. PATIENTS: The patients consisted of 74 women and 47 men with a median age of 54 years (range, 25-79 years). MAIN OUTCOME MEASURES: DNA methylation differences at individual CpG sites and within genes between low- and high-risk patients were compared using the Mann-Whitney test (p < 0.001). RESULTS: A total of 16 CpG loci were differentially methylated (14 increased and 2 decreased) in high- versus low-risk cases. Genes harboring differentially methylated CpG sites included known tumor suppressor genes and novel targets. LIMITATIONS: This study only included patients in the mitomycin-C arm with tumor tissue; however, this sample was representative of the trial. CONCLUSIONS: This is the first study to apply genome-wide methylation analysis to anal cancer. Biologically relevant differences in methylated targets were found to discriminate locally advanced from early anal cancer. Epigenetic events likely play a significant role in the progression of anal cancer and may serve as potential biomarkers.
Authors: Djenaba A Joseph; Jacqueline W Miller; Xiaocheng Wu; Vivien W Chen; Cyllene R Morris; Marc T Goodman; Jose M Villalon-Gomez; Melanie A Williams; Rosemary D Cress Journal: Cancer Date: 2008-11-15 Impact factor: 6.860
Authors: Corinne E Griguer; Alan B Cantor; Hassan M Fathallah-Shaykh; G Yancey Gillespie; Amber S Gordon; James M Markert; Ivan Radovanovic; Virginie Clement-Schatlo; Chevis N Shannon; Claudia R Oliva Journal: PLoS One Date: 2013-04-10 Impact factor: 3.240
Authors: W Weichert; A Röske; V Gekeler; T Beckers; C Stephan; K Jung; F R Fritzsche; S Niesporek; C Denkert; M Dietel; G Kristiansen Journal: Br J Cancer Date: 2008-01-22 Impact factor: 7.640
Authors: Kent W Mouw; James M Cleary; Brendan Reardon; Jonathan Pike; Lior Z Braunstein; Jaegil Kim; Ali Amin-Mansour; Diana Miao; Alexis Damish; Joanna Chin; Patrick A Ott; Charles S Fuchs; Neil E Martin; Gad Getz; Scott Carter; Harvey J Mamon; Jason L Hornick; Eliezer M Van Allen; Alan D D'Andrea Journal: Clin Cancer Res Date: 2016-11-16 Impact factor: 12.531
Authors: Erin M Siegel; Anders E Berglund; Bridget M Riggs; Steven A Eschrich; Ryan M Putney; Abidemi O Ajidahun; Domenico Coppola; David Shibata Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-12 Impact factor: 4.254
Authors: Cecile D Lahiri; Minh Ly Nguyen; C Christina Mehta; Marina Mosunjac; Talaat Tadros; Elizabeth R Unger; Mangalathu S Rajeevan; Jendai Richards; Ighovwerha Ofotokun; Lisa Flowers Journal: Clin Infect Dis Date: 2020-03-03 Impact factor: 9.079
Authors: Iris Eke; Adeola Y Makinde; Molykutty J Aryankalayil; Mansoor M Ahmed; C Norman Coleman Journal: Cancer Lett Date: 2016-01-29 Impact factor: 8.679
Authors: Gilberto Ruiz-Deya; Jaime Matta; Jarline Encarnación-Medina; Carmen Ortiz-Sanchéz; Julie Dutil; Ryan Putney; Anders Berglund; Jasreman Dhillon; Youngchul Kim; Jong Y Park Journal: Int J Mol Sci Date: 2021-01-13 Impact factor: 5.923
Authors: Erin M Siegel; Abidemi Ajidahun; Anders Berglund; Whitney Guerrero; Steven Eschrich; Ryan M Putney; Anthony Magliocco; Bridget Riggs; Kathryn Winter; Jeff P Simko; Jaffer A Ajani; Chandan Guha; Gordon S Okawara; Ibrahim Abdalla; Mark J Becker; Joseph F Pizzolato; Christopher H Crane; Kevin D Brown; David Shibata Journal: PLoS One Date: 2021-12-09 Impact factor: 3.240
Authors: Ramon P van der Zee; Olivier Richel; Carel J M van Noesel; Iuliana Ciocănea-Teodorescu; Annina P van Splunter; Timo J Ter Braak; Mayura Nathan; Tamzin Cuming; Michael Sheaff; Alexander Kreuter; Chris J L M Meijer; Wim G V Quint; Henry J C de Vries; Jan M Prins; Renske D M Steenbergen Journal: Clin Infect Dis Date: 2021-06-15 Impact factor: 9.079